Tuesday, September 11, 2018
Regrowing dental tissue with stem cells from baby teeth
Sometimes kids trip and fall, and their teeth take the hit. Nearly half of children suffer some injury to a tooth during childhood. When that trauma affects an immature permanent tooth, it can hinder blood supply and root development, resulting in what is essentially a "dead" tooth.
Until now, the standard of care has entailed a procedure called apexification that encourages further root development, but it does not replace the lost tissue from the injury and, even in a best-case scenario, causes root development to proceed abnormally.
New results of a clinical trial, jointly led by Songtao Shi of the University of Pennsylvania and Yan Jin, Kun Xuan, and Bei Li of the Fourth Military Medicine University in Xi'an, China, suggest that there is a more promising path for children with these types of injuries: Using stem cells extracted from the patient's baby teeth. The work was published in the journal Science Translational Medicine.
"This treatment gives patients sensation back in their teeth. If you give them a warm or cold stimulation, they can feel it; they have living teeth again," says Shi, professor and chair in the Department of Anatomy and Cell Biology in Penn's School of Dental Medicine. "So far we have follow-up data for two, two and a half, even three years and have shown it's a safe and effective therapy."
Shi has been working for a decade to test the possibilities of dental stem cells after discovering them in his daughter's baby tooth. He and colleagues have learned more about how these dental stem cells, officially called human deciduous pulp stem cells (hDPSC), work and how they could be safely employed to regrow dental tissue, known as pulp.
The Phase I trial, conducted in China, which has a research track for clinical trials, enrolled 40 children who had each injured one of their permanent incisors and still had baby teeth. Thirty were assigned to hDPSC treatment and 10 to the control treatment, apexification.
Those that received hDPSC treatment had tissue extracted from a healthy baby tooth. The stem cells from this pulp were allowed to reproduce in a laboratory culture, and the resulting cells were implanted into the injured tooth.
Upon follow-up, the researchers found that patients who received hDPSCs had more signs than the control group of healthy root development and thicker dentin, the hard part of a tooth beneath the enamel. Blood flow increased as well.
At the time the patients were initially seen, all had little sensation in the tissue of their injured teeth. A year following the procedure, only those who received hDPSCs had regained some sensation. Examining a variety of immune-system components, the team found no evidence of safety concerns.
As further support of the treatment's efficacy, the researchers had the opportunity to directly examine the tissue of a treated tooth when the patient reinjured it and had to have it extracted. They found that the implanted stem cells regenerated different components of dental pulp, including the cells that produce dentin, connective tissue, and blood vessels.
"For me the results are very exciting," Shi says. "To see something we discovered take a step forward to potentially become a routine therapy in the clinic is gratifying."
It is, however, just a first step. While using a patient's own stem cells reduces the chances of immune rejection, it's not possible in adult patients who have lost all of their baby teeth. Shi and colleagues are beginning to test the use of allogenic stem cells, or cells donated from another person, to regenerate dental tissue in adults. They are also hoping to secure FDA approval to conduct clinical trials using hDPSCs in the United States.
Eventually, they see even broader applications of hDPSCs for treating systemic disease, such as lupus, which Shi has worked on before.
"We're really eager to see what we can do in the dental field," Shi says, "and then building on that to open up channels for systemic disease therapy."
Wednesday, August 22, 2018
Biomaterial could keep tooth alive after root canal (video)
A brand-new video on the research is available at http://bit.
"What you end up with after a root canal is a dead tooth," Vivek Kumar, Ph.D., the project's principal investigator, says. "It's no longer responsive. There are no nerve endings or vascular supply. So the tooth is very susceptible to subsequent infection and, ultimately, falling out."
During a root canal, the dentist drills off the top of an infected tooth to access the soft tissue inside. The dentist then removes the infected dental pulp and fills the space with tiny rubber rods called gutta percha and caps the repaired tooth with a crown.
Kumar and Peter Nguyen, Ph.D., who is presenting the work at the meeting, wanted to develop a material that could be injected in place of the gutta percha. The material would stimulate both angiogenesis, or new blood vessel growth, and dentinogenesis, or proliferation of dental pulp stem cells, within the tooth. Both Kumar and Nguyen are at the New Jersey Institute of Technology.
Kumar drew on his previous experience developing a hydrogel that stimulates angiogenesis when injected under the skin of rats and mice. The hydrogel, which is liquid during injection, contains peptides that self-assemble into a gel at the injection site. The peptides contain a snippet of a protein called vascular endothelial growth factor, which stimulates the growth of new blood vessels. Kumar, then a postdoctoral researcher at Rice University, and his coworkers showed that the self-assembling peptide hydrogel stimulated angiogenesis and persisted under the rodents' skin for as long as three months.
"We asked the question, if we can stimulate angiogenesis in a limb, can we stimulate angiogenesis in other regions that have low blood flow?" Kumar says. "One of the regions we were really interested in was an organ in and of itself, the tooth." So Kumar and Nguyen added another domain to the self-assembling angiogenic peptide: a piece of a protein that makes dental pulp stem cells proliferate.
When the team added the new peptide to cultured dental pulp stem cells, they found that the peptide not only caused the cells to proliferate, but also activated them to deposit calcium phosphate crystals -- the mineral that makes up tooth enamel. However, when injected under the skin of rats, the peptide degraded within one to three weeks. "This was shorter than we expected, so we went back and redesigned the peptide backbone so that we currently have a much more stable version," says Kumar.
Now, the team is injecting the peptide hydrogel into the teeth of dogs that have undergone root canals to see if it can stimulate dental pulp regeneration in a living animal. If these studies go well, the researchers plan to move the hydrogel into human clinical studies. They have filed a patent for the redesigned peptide.
The hydrogel in its current form likely won't reduce the invasiveness or pain of a root canal, but Kumar and Nguyen are planning future versions of the peptide that contain antimicrobial domains. "Instead of having to rip out everything inside the tooth, the dentist could go in with a smaller drill bit, remove a little bit of the pulp and inject our hydrogel," Kumar says. The antimicrobial portion of the peptide would kill the infection, preserving more of the existing dental pulp, while helping grow new tissue. And the root canal may no longer be such a dreaded procedure.
A press conference on this topic will be held Wednesday, August 22, at 9 a.m. Eastern time in the Boston Convention & Exhibition Center. Reporters may check-in at the press center, Room 102 A, or watch live on YouTube http://bit.
Monday, August 20, 2018
Bioengineered tooth replacement opens doors to new therapies
Tooth loss is a significant health issue currently affecting millions of people worldwide. While artificial dental implants are the existing standard tooth replacement therapy, they do not exhibit many properties of natural teeth and can be associated with complications leading to implant failure. Two articles published in the September 2018 issue of the Journal of Dental Research share recent advances in bioengineering teeth.
In the article "Bioengineered Tooth Buds Exhibit Features of Natural Tooth Buds" Pamela Yelick, Tufts University School of Dental Medicine, Boston, Mass., USA and co-authors explored new methods to create highly cellularized bioengineered tooth bud constructs that include features that resemble natural tooth buds such as the dental epithelial stem cell niche, enamel knot signaling centers, transient amplifying cells and mineralized dental tissue formation. The constructs were composed of postnatal dental cells encapsulated within a hydrogel material that were implanted subcutaneously into immunocompromised rats.
This is the first report that describes the use of postnatal dental cells to create bioengineered tooth buds that exhibit evidence of these features of natural tooth development, pointing to future bioengineered tooth buds as a promising, clinically relevant tooth replacement therapy.
In the article "Bone Marrow Stromal Cells Promote Innervation of Bioengineered Teeth" Sabine Kuchler-Bopp, French National Institute of Health and Medical Research and Fédération de Médecine Translationnelle de Strasbourg, France, and co-authors developed a strategy where autologous mesenchymal cells coming from bone marrow can be used to supply nerves to bioengineered teeth without treatment that uses an immunosuppressor. The innervation of teeth is essential for their function and protection but does not occur spontaneously after injury. This new method provides innervation while avoiding multiple side effects associated with immunosuppressors.
"These exciting studies point to a promising future for bioengineered teeth," said Journal of Dental Research Editor-in-Chief William V. Giannobile. "This cutting-edge research has the potential to advance tooth replacement therapy and the science base to bring such regenerative medicine treatments to improve clinical care."
###
Thursday, August 9, 2018
Dental care may benefit patients scheduled for cancer surgery
Of 509,179 patients studied, 16% received preoperative oral care from a dentist. When a surgeon requested that a dentist provide preoperative oral care to a patient with cancer, the dentist checked the patient's oral condition, provided professional tooth cleaning, taught the patient self-cleaning methods for the teeth, and provided any treatment needed.
In the study, 15,724 patients (3.09%) developed postoperative pneumonia and 1734 (0.34%) died within 30 days of surgery. After adjustments, preoperative oral care by a dentist was linked with a decrease in postoperative pneumonia (3.28% versus 3.76%) and death within 30 days (0.30% versus 0.42%).
"The findings could help improve strategies for the prevention of postoperative complications," the authors wrote.
Wednesday, August 8, 2018
Unwise opioids for wisdom teeth: Study shows link to long-term use in teens and young adults
Getting wisdom teeth removed may be a
rite of passage for many teens and young adults, but the opioid
painkiller prescriptions that many of them receive could set them on a
path to long-term opioid use, a new study finds.
Young people ages 13 to 30 who filled an opioid prescription
immediately before or after they had their wisdom teeth out were nearly
2.7 times as likely as their peers to still be filling opioid
prescriptions weeks or months later, according to new research from a
University of Michigan team.
Those in their late teens and twenties had the highest odds of persistent opioid use, compared with those of middle school and high school age, the researchers report in a research letter in the new issue of JAMA.
Led by Calista Harbaugh, M.D., a U-M research fellow and surgical resident, the researchers used insurance data to focus on young people who were 'opioid naïve' -- who hadn't had an opioid prescription in the six months before their wisdom teeth came out, and who didn't have any other procedures requiring anesthesia in the following year.
"Wisdom tooth extraction is performed 3.5 million times a year in the United States, and many dentists routinely prescribe opioids in case patients need it for post-procedure pain," says Harbaugh, a National Clinician Scholar at the U-M Institute for Healthcare Policy and Innovation. "Until now, we haven't had data on the long-term risks of opioid use after wisdom tooth extraction. We now see that a sizable number go on to fill opioid prescriptions long after we would expect they would need for recovery, and the main predictor of persistent use is whether or not they fill that initial prescription."
Other factors also predicted risk of long-term opioid use. Teens and young adults who had a history of mental health issues such as depression and anxiety, or chronic pain conditions, were more than others to go on to persistent use after filling their initial wisdom tooth-related prescription.
More about the study
In all, 1.3 percent of 56,686 wisdom tooth patients who filled their opioid prescription between 2009 and 2015 went on to persistent opioid use, defined as two or more prescriptions filled in the next year written by any provider for any reason. That's compared with 0.5 percent of the 14,256 wisdom tooth patients who didn't fill a prescription.
Though those numbers may seem small, the high number of wisdom teeth procedures every year mean a large number of young people are at risk, notes Harbaugh, a research fellow with the Michigan Opioid Prescribing and Engagement Network, or Michigan OPEN.
The team used data from employer-based insurance plans, available through the Truven MarketScan database purchased for researchers' use by IHPI. Chad Brummett, M.D., co-director of Michigan OPEN, is senior author of the new research, and the team includes U-M School of Dentistry professor Romesh Nalliah, D.D.S., MHCM.
The data show opioid prescriptions filled, but not actual use of opioid pills by patients. Leftover opioids pose a risk of their own, because they can be misused by the individual who received the prescription, or by a member of their household or a visitor. The researchers also couldn't tell the reason for the later opioid prescription fills by those who went on to persistent use.
The authors suggest that dentists and oral surgeons should consider prescribing non-opioid painkillers before opioids to their wisdom tooth patients. If pain is acute, they should prescribe less than the seven-day opioid supply recently recommended by the American Dental Association for any acute dental pain.
"There are no prescribing recommendations specifically for wisdom tooth extraction," says Harbaugh. "With evidence that nonsteroidal anti-inflammatories may just as, if not more, effective, a seven-day opioid recommendation may still be too much."
Brummett adds, "These are some of the first data to the show long-term ill effects of routine opioid prescribing after tooth extractions. When taken together with the previous studies showing that opioids are not helpful in these cases, dentists and oral surgeons should stop routinely prescribing opioids for wisdom tooth extractions and likely other common dental procedures."
Importance for patients and parents
Getting a prescription for an opioid painkiller around the time of a wisdom tooth procedure comes with many decision points, Harbaugh says.
"Patients must decide whether to fill the prescription and take the medication, and where to store and dispose of the unused pills. All of these decision points need to be discussed with patients," she says. "Patients should talk to their dentists about how to control pain without opioids first. If needed, opioids should only be used for breakthrough pain, as backup if the pain's not controlled with other medications."
The Michigan-OPEN team is currently studying the wisdom tooth extraction population further, by speaking with patients and parents about their experience and how many opioid pills they actually took. This will allow them to create evidence-based prescribing guidelines just like the ones they've developed for other operations.
The research was funded by the federal Substance Abuse and Mental Health Services Administration, the Michigan Department of Health and Human Services, and the University of Michigan Precision Health Initiative.
Those in their late teens and twenties had the highest odds of persistent opioid use, compared with those of middle school and high school age, the researchers report in a research letter in the new issue of JAMA.
Led by Calista Harbaugh, M.D., a U-M research fellow and surgical resident, the researchers used insurance data to focus on young people who were 'opioid naïve' -- who hadn't had an opioid prescription in the six months before their wisdom teeth came out, and who didn't have any other procedures requiring anesthesia in the following year.
"Wisdom tooth extraction is performed 3.5 million times a year in the United States, and many dentists routinely prescribe opioids in case patients need it for post-procedure pain," says Harbaugh, a National Clinician Scholar at the U-M Institute for Healthcare Policy and Innovation. "Until now, we haven't had data on the long-term risks of opioid use after wisdom tooth extraction. We now see that a sizable number go on to fill opioid prescriptions long after we would expect they would need for recovery, and the main predictor of persistent use is whether or not they fill that initial prescription."
Other factors also predicted risk of long-term opioid use. Teens and young adults who had a history of mental health issues such as depression and anxiety, or chronic pain conditions, were more than others to go on to persistent use after filling their initial wisdom tooth-related prescription.
More about the study
In all, 1.3 percent of 56,686 wisdom tooth patients who filled their opioid prescription between 2009 and 2015 went on to persistent opioid use, defined as two or more prescriptions filled in the next year written by any provider for any reason. That's compared with 0.5 percent of the 14,256 wisdom tooth patients who didn't fill a prescription.
Though those numbers may seem small, the high number of wisdom teeth procedures every year mean a large number of young people are at risk, notes Harbaugh, a research fellow with the Michigan Opioid Prescribing and Engagement Network, or Michigan OPEN.
The team used data from employer-based insurance plans, available through the Truven MarketScan database purchased for researchers' use by IHPI. Chad Brummett, M.D., co-director of Michigan OPEN, is senior author of the new research, and the team includes U-M School of Dentistry professor Romesh Nalliah, D.D.S., MHCM.
The data show opioid prescriptions filled, but not actual use of opioid pills by patients. Leftover opioids pose a risk of their own, because they can be misused by the individual who received the prescription, or by a member of their household or a visitor. The researchers also couldn't tell the reason for the later opioid prescription fills by those who went on to persistent use.
The authors suggest that dentists and oral surgeons should consider prescribing non-opioid painkillers before opioids to their wisdom tooth patients. If pain is acute, they should prescribe less than the seven-day opioid supply recently recommended by the American Dental Association for any acute dental pain.
"There are no prescribing recommendations specifically for wisdom tooth extraction," says Harbaugh. "With evidence that nonsteroidal anti-inflammatories may just as, if not more, effective, a seven-day opioid recommendation may still be too much."
Brummett adds, "These are some of the first data to the show long-term ill effects of routine opioid prescribing after tooth extractions. When taken together with the previous studies showing that opioids are not helpful in these cases, dentists and oral surgeons should stop routinely prescribing opioids for wisdom tooth extractions and likely other common dental procedures."
Importance for patients and parents
Getting a prescription for an opioid painkiller around the time of a wisdom tooth procedure comes with many decision points, Harbaugh says.
"Patients must decide whether to fill the prescription and take the medication, and where to store and dispose of the unused pills. All of these decision points need to be discussed with patients," she says. "Patients should talk to their dentists about how to control pain without opioids first. If needed, opioids should only be used for breakthrough pain, as backup if the pain's not controlled with other medications."
The Michigan-OPEN team is currently studying the wisdom tooth extraction population further, by speaking with patients and parents about their experience and how many opioid pills they actually took. This will allow them to create evidence-based prescribing guidelines just like the ones they've developed for other operations.
The research was funded by the federal Substance Abuse and Mental Health Services Administration, the Michigan Department of Health and Human Services, and the University of Michigan Precision Health Initiative.
Tuesday, July 31, 2018
Dental plaque is no match for catalytic nanoparticles
In a study published in Nature Communications this week, researchers led by Hyun (Michel) Koo of the University of Pennsylvania School of Dental Medicine in collaboration with David Cormode of Penn's Perelman School of Medicine and School of Engineering and Applied Science used FDA-approved nanoparticles to effectively disrupt biofilms and prevent tooth decay in both an experimental human-plaque-like biofilm and in an animal model that mimics early-childhood caries.
The nanoparticles break apart dental plaque through a unique pH-activated antibiofilm mechanism.
"It displays an intriguing enzyme-like property whereby the catalytic activity is dramatically enhanced at acidic pH but is 'switched off' at neutral pH conditions," says Koo, professor in Penn Dental Medicine's Department of Orthodontics and in the divisions of Pediatric Dentistry and Community Oral Health. "The nanoparticles act as a peroxidase, activating hydrogen peroxide, a commonly used antiseptic, to generate free radicals that potently dismantle and kill biofilms in pathological acidic conditions but not at physiological pH, thus providing a targeted effect."
Because the caries-causing plaque is highly acidic, the new therapy is able to precisely target areas of the teeth harboring pathogenic biofilms without harming the surrounding oral tissues or microbiota.
The particular iron-containing nanoparticle used in the experiments, ferumoxytol, is already FDA-approved to treat iron-deficiency, a promising indication that a topical application of the same nanoparticle, used at several-hundred-fold lower concentration, would also be safe for human use.
Though some scientists have questioned whether coatings used on ferumoxytol and other nanoparticles used for medical applications would render them catalytically inert, Koo, Liu, and Cormode demonstrated that they maintained peroxidase-like activity, activating hydrogen peroxide.
After testing the ferumoxytol-hydrogen peroxide combination on a tooth-enamel-like material, the team moved on to an experimental set-up that more closely replicated the conditions of the human mouth.
"We used plaque samples from caries-active subjects to reconstruct these highly pathogenic biofilms on real human tooth enamel," says Koo. "This simulation showed that our treatment not only disrupts the biofilm but also prevents mineral destruction of the tooth's surface. That offered very strong evidence that this could work in vivo."
Further studies in a rodent model that closely mirrors the stages of caries development in humans showed that twice-a-day rinses of ferumoxytol and hydrogen peroxide greatly reduced the severity of caries on all of the surfaces of the teeth and also completely blocked the formation of cavities in the enamel.
As further evidence of the treatment's targeted effect, the researchers found no significant change in the diversity of microbes in the mouth after therapy and found no signs of tissue damage.
"This therapy isn't killing microorganisms indiscriminately," Koo says, "but rather it is acting only where the pathological biofilm develops. Such a precise therapeutic approach can target the diseased sites without disrupting the ecological balance of the oral microbiota, which is critical for a healthy mouth, while also avoiding infection by opportunistic pathogens."
Incorporating nanoparticles in a mouth rinse or toothpaste could be a cost-effective way to significantly improve their effectiveness, says Koo. Many of these products already contain hydrogen peroxide and would only require the addition of a small amount of relatively inexpensive nanoparticles. With evidence backing this approach in both an animal model and a human-like model of tooth decay, the research team is actively working to test its clinical efficacy.
Thursday, July 19, 2018
The effectiveness of chlorhexidine is limited in preventing infections in oral procedures
The human oral cavity is colonised by a huge variety of bacteria. When surgical procedures such as a tooth extraction are carried out, the bacteria can pass into the bloodstream causing bacteraemia that is generally transient. What is not yet clear is how significant this presence of bacteria in the blood is in terms of the origin and evolution of infectious processes such as endocarditis of the heart valves, prosthetic valves, hip and knee joint replacements generally, and in local infection.
Numerous studies have shown that a mouthwash containing chlorhexidine has a powerful antimicrobial effect on saliva microflora and bacterial plaque. "On the basis of this hypothesis we can assume that antimicrobial mouthwashes used before the dental procedure should reduce the number of micro-organisms that pass into the patient's bloodstream, yet this is a hotly debated issue," said the members of the UPV/EHU's research group.
In 1997 the American Heart Association (AHA) suggested that patients at risk of infectious endocarditis should use an antimicrobial mouthwash before a dental procedure. In 2006, the British Society for Antimicrobial Chemotherapy (BSAC) recommended a single mouthwash with 0.2% chlorhexidine (CHX) (10 ml for 1 minute) before the carrying out of dental procedures associated with bacteraemia in patients at risk. Yet in 2007 the AHA recommended against adopting any antiseptic prophylaxis protocol.
In an effort to shed scientific light on this issue, the UPV/EHU research group comprising Iciar Arteagoitia, Carlos Rodriguez-Andrés and Eva Ramos decided to conduct a systematic review and meta-analysis of random controlled trials (RCT), following the PRISMA Statement. The aim was to assess the effectiveness of chlorhexidine in preventing bacteraemia following a tooth extraction. The research was conducted in collaboration with the UPV/EHU's Department of Epidemiology and was published in Plos One, the leading, open-access, global scientific journal which accepts rigorous, innovative papers on scientific research.
In the study that included 8 clinical trials with 523 patients there were 267 in the group treated with chlorhexidine, in which 145 cases of bacteraemia were recorded, and 256 in the control group, in which there were 156 cases of bacteraemia. The results of the research therefore indicate that the percentage of cases of bacteraemia that can be prevented if a population undergoes chlorhexidine-based prevention is 12%. The NNT, the number of patients that need to be treated to prevent bacteraemia, is 16.
The results point to the relative and not particularly significant effectiveness of the use of chlorhexidine when it comes to preventing the bacteria present in the mouth from passing into the bloodstream when dental extraction is carried out. "Yet, given its low cost and the absence of adverse reactions and complications, we would recommend a mouthwash with chlorhexidine before a procedure of this type is carried out," concluded the UPV/EHU's research group.
Subscribe to:
Posts (Atom)